HER2 Support Group Forums - View Single Post - Precision highlights role of ChemoFx test, multi-gene predictors for breast cancer

gdpawel · 01-23-2011, 02:13 PM

Precision Therapeutics Announced A New Tumor Profiling Product To Augment Utility Of ChemoFx And Further Personalize Cancer Treatment

Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx, will help further the personalization of cancer treatments. BioSpeciFx is composed of carefully selected sets of well validated and clinically useful biomarker tests that identify critical molecular targets within a patient's cell. By using the information generated by BioSpeciFx in combination with Precision's sophisticated drug response marker ChemoFx, physicians may gain a more complete understanding of a patient's tumor.

When combined, both products offer a complementary sum of information which will enable physicians to look at both the relevant molecular targets as well as the synergistic activity of drug combinations on the entire cell. BioSpeciFx provides proteomic and genomic information, while ChemoFx takes into account all of the functional characteristics of a tumor including those not captured by biomarker testing, providing both sensitivity and resistance information.

"The Comprehensive Tumor Profile developed by Precision presents the most complete offering available to cancer patients today, because it integrates both genomic and proteomic information with the functional profiling of ChemoFx," says Sean McDonald, CEO of Precision Therapeutics. "We are very excited to provide physicians with a closer look at each patient's tumor as we continue to develop products aimed at personalizing treatments for cancer patients."

Source: Precision Therapeutics

Precision Therapeutics is using ChemoFx as a complement to BioSpeciFx. They run ChemoFx on a population of tumors (i.e. breast cancer). They identify the responsive, intermediately responsive, and non-responsive patients. Then they take the molecular markers and find out what these patients have in common with respect to 150 different genes. Then they work on eliminating the genes that are irrelevant.

What they get is a multi-gene predictor. It can't work without ChemoFx working. They claim their MGP for breast cancer is accurate 85% of the time according to MD Anderson and US Oncology. Each drug has it's own signature, but couldn't happen if ChemoFx wasn't accurate. ChemoFx is the backbone of MGP. The oncologist can pick and choose which markers he/she wants to see.

01-23-2011, 02:13 PM	#2
gdpawel Senior Member Join Date: Aug 2006 Location: Pennsylvania Posts: 1,080	RT-PCR and DNA Microarrays in Personalized Oncology Precision Therapeutics Announced A New Tumor Profiling Product To Augment Utility Of ChemoFx And Further Personalize Cancer Treatment Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx, will help further the personalization of cancer treatments. BioSpeciFx is composed of carefully selected sets of well validated and clinically useful biomarker tests that identify critical molecular targets within a patient's cell. By using the information generated by BioSpeciFx in combination with Precision's sophisticated drug response marker ChemoFx, physicians may gain a more complete understanding of a patient's tumor. When combined, both products offer a complementary sum of information which will enable physicians to look at both the relevant molecular targets as well as the synergistic activity of drug combinations on the entire cell. BioSpeciFx provides proteomic and genomic information, while ChemoFx takes into account all of the functional characteristics of a tumor including those not captured by biomarker testing, providing both sensitivity and resistance information. "The Comprehensive Tumor Profile developed by Precision presents the most complete offering available to cancer patients today, because it integrates both genomic and proteomic information with the functional profiling of ChemoFx," says Sean McDonald, CEO of Precision Therapeutics. "We are very excited to provide physicians with a closer look at each patient's tumor as we continue to develop products aimed at personalizing treatments for cancer patients." Source: Precision Therapeutics Precision Therapeutics is using ChemoFx as a complement to BioSpeciFx. They run ChemoFx on a population of tumors (i.e. breast cancer). They identify the responsive, intermediately responsive, and non-responsive patients. Then they take the molecular markers and find out what these patients have in common with respect to 150 different genes. Then they work on eliminating the genes that are irrelevant. What they get is a multi-gene predictor. It can't work without ChemoFx working. They claim their MGP for breast cancer is accurate 85% of the time according to MD Anderson and US Oncology. Each drug has it's own signature, but couldn't happen if ChemoFx wasn't accurate. ChemoFx is the backbone of MGP. The oncologist can pick and choose which markers he/she wants to see.